Veracyte Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.1%projected annual EPS growth
Analyst Coverage
11analysts covering
FY Revenue (est.)
$593.6Mnext fiscal year
FY EPS (est.)
$1.91next fiscal year
Monitoring Framework
Key Performance Indicators
Total Testing Volume Quarterly47.6K
Decipher Test Revenue Quarterly86.5M
Afirma Test Revenue Quarterly46.4M
Non-GAAP Gross Margin Quarterly
Watch Items
- Commercial launch and adoption of TrueMRD platform in muscle-invasive bladder cancer (MIBC)Trigger: Guideline inclusion and commercial adoption following the June 1, 2026 launch and MolDX Medicare coverage decision.Action: Monitor commercial adoption, quarterly testing volume contributions, and data readouts from ongoing clinical trials such as TOMBOLA and NEO-BLAST.
- U.S. commercial rollout of the Prosigna Breast Cancer Test as a Laboratory Developed Test (LDT)Trigger: Physician adoption rates and volume growth in breast cancer testingAction: Evaluate product revenue transition to high-margin testing revenue
Research as of 19 Jun 2026